Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enzyme Research
Reports outline enzyme research from Exelixis, Inc.
May 16th, 2008
New research, 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation,' is the subject of a report. According to a study from the United States, "Mutations associated with resistance to kinase inhibition are an important mechanism of intrinsic or acquired loss of clinical efficacy for kinase-targeted therapeutics. We report the prospective discovery of ErbB2 mutations that confer resistance to the small-molecule inhibitor lapatinib." "We did in vitro screening using a randomly mutagenized ErbB2 expression library in Ba/F3 cells, which were dependent on ErbB2 activity for survival and growth. Lapatinib resistance...
Source: Health Business Week (2008-05-16)
|
